Aurinia Pharmaceuticals (AUPH) Long-Term Deferred Tax (2025 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Long-Term Deferred Tax came in at $166.9 million in Q1 2026, down 5.27% on a QoQ basis from $176.2 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 2 years of Long-Term Deferred Tax data on file, last reported at $166.9 million in Q1 2026.
- Quarterly Long-Term Deferred Tax changed N/A year-over-year to $166.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.9 million (changed N/A YoY) and the FY2025 annual result came in at $176.2 million, changed N/A from the prior year.
- Long-Term Deferred Tax slipped to $166.9 million in Q1 2026, from $176.2 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $176.2 million in Q4 2025 to a low of $166.9 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 178.94 Mn |
| Mar 31, 2026 | 166.92 Mn |
| Dec 31, 2025 | 176.19 Mn |